l T T l James O'Neil Topline Summary and Update The market has been much more confident in the outlook for SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) than I was in my first coverage of the company back in December immediately following their first drug approval. Indeed, multiple analysts have since presented articles echoing that SWTX maintains an unclear risk to reward potential, given the potential market size for their main drug relative to the multi-billion dollar market valuation. Today, we have the ...

Q2 2024 Financial Results and Business Update August 7, 2024 之 Spring 2 Today's Agenda | --- | --- | |----------------------------|--------------------------------------------| | Sections | Presenter(s) | | Opening Remarks | Saqib Islam Chief Executive Officer | | OGSIVEO for Desmoid Tumors | Bhavesh Ashar Chief Commercial Officer | | Mirdametinib for NF1-PN | Jim Cassidy, MD, PhD Chief Medical Officer | | Financial Results | Frank Perier, Jr. Chief Financial Officer | | Looking Ahead | Saqib Islam Chief Ex ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q2 2024 Earnings Conference Call August 7, 2024 8:30 AM ET Company Participants Samantha Sandler - Senior Director of IR Saqib Islam - CEO Bhavesh Ashar - Chief Commercial Officer Jim Cassidy - CMO Frank Perier - CFO Badreddin Edris - COO Conference Call Participants Anupam Rama - JPMorgan Yaron Werber - TD Cowen Corinne Johnson - Goldman Sachs Peter Lawson - Barclays Michael Schmidt - Guggenheim Alec Stranahan - Bank of America Operator Good morning. My name is ...

SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $1.12. This compares to loss of $1.25 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 51.79%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.17 per share when it actually produced a loss of $1.18, delivering a surprise of -0.85%. Over the last four quart ...

Exhibit 99.1 SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights ® – Achieved $40.2 million in OGSIVEO (nirogacestat) net product revenue in the second quarter – – Completed submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1- PN – – Presented Phase 2b ReNeu trial results and additional analyses from Phase 3 DeFi trial at the 2024 ASCO Annual Meeting – – Initiated Phase 1a trial of SW-682 in patients with Hippo mut ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________________________________________ FORM 10-Q ____________________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _ TO _ COMMISSION FILE NUMBER 001-39044 ______ ...

– Achieved $40.2 million in OGSIVEO® (nirogacestat) net product revenue in the second quarter – – Completed submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1-PN – – Presented Phase 2b ReNeu trial results and additional analyses from Phase 3 DeFi trial at the 2024 ASCO Annual Meeting – – Initiated Phase 1a trial of SW-682 in patients with Hippo mutant solid tumors – STAMFORD, Conn., Aug. 07, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), ...

– Achieved $40.2 million in OGSIVEO® (nirogacestat) net product revenue in the second quarter – – Completed submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1-PN – – Presented Phase 2b ReNeu trial results and additional analyses from Phase 3 DeFi trial at the 2024 ASCO Annual Meeting – – Initiated Phase 1a trial of SW-682 in patients with Hippo mutant solid tumors – STAMFORD, Conn., Aug. 07, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), ...

STAMFORD, Conn., July 29, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the appointment of Martin Mackay, Ph.D. to the Company's Board of Directors. Dr. Mackay is a highly accomplished research and development (R&D) executive with more than 30 years of pharmaceutical and biotech R&D experience, including leadership roles at Pfizer, AstraZeneca and Alexion. "Martin is a proven in ...

STAMFORD, Conn., July 29, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the appointment of Martin Mackay, Ph.D. to the Company's Board of Directors. Dr. Mackay is a highly accomplished research and development (R&D) executive with more than 30 years of pharmaceutical and biotech R&D experience, including leadership roles at Pfizer, AstraZeneca and Alexion. "Martin is a proven in ...